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Abstract  Clinicians  should  consider  and  approach  inﬂammatory  bowel  diseases  as  a  multisys-
temic disease.  Though  neurologic  complications  related  to  inﬂammatory  bowel  diseases  are  not
rare, they  are  frequently  underdiagnosed  when  compared  with  other  organ  complications.
We report  on  a  40-year-old  patient  with  severe  Crohn’s  disease  and  an  acquired  demyelinat-
ing polyneurophathy,  malnourished,  on  biological  therapy,  who  was  admitted  in  our  institution
with an  opportunistic  infection  (esophageal  candidiasis).  After  successful  treatment  of  infec-
tious complication,  he  maintained  unexplained  dysphagia  and  gastric  stasis  requiring  parenteral
nutrition. Some  weeks  later  he  presented  with  ophthalmoplegia  and  cognitive  impairment.  A
clinical diagnosis  of  Wernicke  encephalopathy  was  suspected  despite  multivitamin  infusion  in
standard  doses.  After  high  doses  of  intravenous  thiamine,  dysphagia  and  gastroparesis  improved
substantially.
Wernicke encephalopathy  is  unusual  in  inﬂammatory  bowel  diseases  patients  and  dysphagia
is a  very  rare  symptom  of  thiamine  deﬁciency.
© 2013  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Distúrbio  neurológico  agudo  na  doenc¸a de  Crohn:  uma  complicac¸ão  grave  e  rara
Resumo  A  doenc¸a  inﬂamatória  intestinal  deve  ser  considerada  e  abordada  clinicamente
como uma  patologia  multissistémica.  Apesar  das  complicac¸ões  neurológicas  relacionadas  com  a
doenc¸a inﬂamatória  intestinal  não  serem  raras,  são  frequentemente  subdiagnosticadas  quandoEncefalopatia  de comparadas  com  as  complicac¸ões  que  afetam  outros  órgãos.
o  de  um  doente  de  40  anos  com  doenc¸a  de  Crohn  severa  e  umaWernicke; Reportamos  o  caso  clínicPerturbac¸ões  da
deglutic¸ão
polineuropatia  desmielinizante  adquirida,  subnutrido,  medicado  com  terapêutica  biológica,
admitido  na  nossa  instituic¸ão  por  uma  infec¸ão  oportunista  (candidíase  esofágica).  Após  o
tratamento  eﬁcaz  da  complicac¸ão  infeciosa  manteve  disfagia  e  estase  gástrica  não  expli-
cadas, necessitando  de  nutric¸ão  parentérica.  Algumas  semanas  mais  tarde  foram  objetivadas
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oftalmoplegia  e  alterac¸ões  cognitivas.  Suspeitou-se,  pelo  quadro  clínico,  de  encefalopatia
de Wernicke,  apesar  da  administrac¸ão  parentérica  de  suplemento  multivitamínico  em  doses
standard. Foi  administrada,  empiricamente,  tiamina  por  via  endovenosa  em  doses  elevadas,
com melhoria  clínica  signiﬁcativa,  nomeadamente,  da  disfagia  e  gastroparésia.
A encefalopatia  de  Wernicke  é  uma  complicac¸ão  infrequente  em  doentes  com  doenc¸a  inﬂa-
matória intestinal  e  a  disfagia  relacionada  com  déﬁce  de  tiamina  é  um  sintoma  muito  raro.
© 2013  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos  reservados.
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nﬂammatory  bowel  disease  (IBD),  Crohn’s  disease  (CD)
nd  Ulcerative  colitis  (UC)  should  be  approached  as  mul-
isystemic  diseases.  Extraintestinal  manifestations  in  IBD
re  widely  recognized,  sometimes  precede  intestinal  symp-
oms  or  have  a  more  severe  behavior  than  gastrointestinal
nvolvement.  On  the  other  hand,  complications  secondary
o  medications  can  involve  virtually  any  organ  or  system.
Neurologic  complications  are  not  infrequent  but  are  less
ecognized  when  compared  to  other  organ  complications.
ifferent  mechanisms  are  believed  to  be  involved  in  the
athogenesis  of  central  and  peripheral  nervous  system
isorders,  which  may  present  separately  or  in  combina-
ion.  Neurologic  manifestations  in  patients  with  IBD  can
e  ascribed  to  several  pathophysiological  mechanisms,  one
eing  malabsorption  and  nutritional  deﬁciencies  (particu-
arly  vitamin  B1,  B12,  D,  E,  folic  acid  and  nicotinamide).1,2 In
ddition,  unspeciﬁed  neuronal  inﬂuence  of  enteric  disease
nto  the  nervous  system  (and  vice  versa)  can  hypothetically
lay  a  role,  based  on  contemporary  theories  considering  the
xistence  of  a  brain-gut  axis,  as  well  as  from  studies  on
unctional  neuroimaging.3,4
ase report
he  patient  was  diagnosed  with  CD  in  2001  at  the  age
f  31,  after  surgery  for  intestinal  obstruction  at  another
nstitution,  resulting  in  ileocaecal  resection  with  ileocolonic
nastomosis.  In  2004  he  was  evaluated  for  the  ﬁrst  time  in
ur  institution.  At  the  initial  observation,  he  complained
f  intermittent  diarrhea  and  weigh  loss.  He  had  a  body
ass  index  (BMI)  of  19.53  kg/m2 and  was  medicated  with
teroids  for  a  long  time  (steroid-dependent).  After  further
valuation  with  blood  tests,  endoscopic  and  imaging  stud-
es  he  began  treatment  with  azathioprine.  The  following
ear,  the  disease  maintained  a  high  level  of  activity  (abdom-
nal  pain,  diarrhea  and  weigh  loss),  and  anti-tumor  necrosis
actor  (TNF)    therapy  was  initiated  (inﬂiximab  5  mg/kg).
n  2007,  during  clinical  remission,  he  was  diagnosed  with
sophageal  candidiasis.  At  that  time  azathioprine  was  dis-
ontinued.  In  2009,  he  had  a  clinical  relapse  and  inﬂiximab
osage  was  adjusted  to  10  mg/kg  every  8  weeks.  In  February
010,  disease  was  still  active,  the  patient  continued  to  lose
eight  (BMI  13.47)  and  a  biological  switch  to  adalimumab
as  attempted.
In  October  2010  the  patient  complained  for  the  ﬁrst
ime  of  progressive  paraesthesias  in  both  feet  and  hands
p
i
t
tnd  muscular  weakness  in  upper  and  lower  limbs.  He
ould  not  specify  the  time  of  onset  of  the  symptoms
several  years)  but  mentioned  an  aggravation  in  the
revious  month.  He  was  evaluated  in  the  Neurology  depart-
ent  and  an  acquired  demyelinating  polyneurophathy  was
iagnosed.  Chronic  inﬂammatory  demyelinating  polyneu-
ophathy  related  to  anti-TNF  therapy  was  suspected  but,
ecause  those  symptoms  had  been  present  for  several  years,
 causal  relationship  was  difﬁcult  to  establish.  We  decided  to
top  anti-TNF  therapy  and  steroids  were  started,  without
linical  improvement.
Short  afterwards,  in  November  2010,  he  presented  with
ysphagia.  Endoscopic  evaluation  revealed  lesions  sugges-
ive  of  severe  esophageal  candidiasis.  Chest  radiography  also
evealed  an  inﬁltrate  in  the  left  lung  suggesting  pneumo-
ia.  He  began  antibiotics,  anti-fungic  and  enteral  nutrition
nasogastric  feeding  tube).
After  two  weeks,  upper  endoscopy  was  repeated  and  no
sophageal  lesions  were  observed.  The  nasogastric  feeding
ube  was  removed;  however,  the  patient  maintained  com-
laints  of  dysphagia  and  began  vomiting.
In December  parenteral  nutrition  was  prescribed,
djusted  to  caloric  requirements  with  multivitamin  infu-
ion  and  trace  elements  supplementation.  Concomitantly,
nteral  nutrition  (nasoenteric  feeding  tube)  was  also  initi-
ted  to  stimulate  gut  protection  and  function.
Three  weeks  later,  he  presented  dyspnea  and  chest  radio-
raphy  revealed  pneumonia  in  the  right  lung  with  pleural
ffusion.  Empirical  antibiotic  therapy  was  restarted  and  a
ight  thoracocentesis  was  performed.  The  following  day,
hest  radiography  revealed  a  right  pneumothorax  and  a  tho-
acic  drain  was  placed.
One  week  later,  respiratory  complications  were  resolved
ut  esophageal  and  gastric  dysfunctions  were  still  present.
he  patient  was  severely  malnourished  (BMI:  10.93  kg/m2)
ith  muscular  atrophy  and  complained  of  visual  impairment.
n  neurologic  evaluation,  diplopia  and  limitation  of  eye
ovements  were  detected.
Three  days  later  he  presented  unusual  behavior  and
isorientation.  A  cranial  computed  tomography  scan  was
btained  and  acute  vascular  lesions  were  excluded.  Wer-
icke  encephalopathy  (WE)  was  suspected  based  in  clinical
vidence,  despite  multivitamin  supplementation  in  par-
nteral  nutrition.  Laboratory  tests  to  assess  thiamine
evels  and  Magnetic  Resonance  Imaging  (MRI)  were  not
romptly  available.  Empiric  treatment  with  high  doses  of
ntravenous  thiamine  (200  mg  3  times  daily)  was  adminis-
rated  due  to  the  low  incidence  of  adverse  effects  of  the
reatment.
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In  the  ﬁrst  24  h  of  treatment,  a  signiﬁcant  improvement
was  observed.  The  patient  no  longer  presented  signs  of  ence-
phalopathy.  Eye  movements  normalized  during  the  following
week.  Oral  feeding  was  restarted,  successfully,  without  dys-
phagia  or  vomiting.  The  patient  was  later  discharged,  on
daily  oral  multivitamin  supplementation  and  intramuscu-
lar  thiamine  100  mg/day,  which  he  maintained  for  several
months.
In  March  2011,  anti-TNF  therapy  was  reinitiated,  with
clinical  remission  of  CD  and  mild  neurologic  complaints,  with
a  relapsing-remitting  pattern.
Discussion
The  case  report  aims  at  highlighting  acute  neurologic  mani-
festations  in  a  patient  with  severe  CD.
Malnutrition  and  weight  loss  are  frequently  observed  in
patients  with  IBD,  especially  CD.  This  condition  can  result
from  multiple  factors,  including  reduced  food  intake,  mal-
absorption,  diarrhea  and  oxidative  stress,  all  of  which  can
be  worsened  by  disease  activity.5
Filippi  et  al,  evaluated  54  consecutive  CD  patients  in  clin-
ical  remission,  assessing  body  composition,  resting  energy
expenditure,  nutrient  intake,  and  plasma  concentration.
These  patients  were  compared  to  25  healthy  controls.
According  to  their  results  macronutrient  needs  are  usually
covered  by  food  intake  when  patients  are  in  remission;  how-
ever,  micronutrient  deﬁciencies  are  frequent  and  call  for
speciﬁc  screening  and  treatment.6
Our  patient  was  malnourished  for  a  long  period  of  time,
probably  even  before  CD  diagnosis,  which  may  explain  his
low  stature  and  weight.  When  the  disease  was  active  his
nutritional  status  worsened  despite  oral  nutritional  supple-
ments  administration.
In  November  2010,  when  he  was  admitted  with  severe
esophageal  candidiasis,  his  nutritional  condition  was  poor
and  adjusted  nutritional  support  was  provided.  The  infec-
tious  intercurrences  related  to  his  immunosuppressed
condition  were  life-threatening  but  were  successfully
treated.  When  he  presented  with  ophthalmoplegia  and  cog-
nitive  impairment,  clinical  diagnosis  of  WE  was  suspected,
although  standard  parenteral  multivitamin  supplementation
was  being  provided.  The  clinical  improvement  after  thi-
amine  infusion  conﬁrmed  the  diagnosis.
The  resolution  of  dysphagia  and  gastroparesis  with  thi-
amine  administration  suggests  that  these  symptoms  were
also  related  to  thiamine  deﬁciency,  and  in  this  particular
case,  were  early  symptoms.
Thiamine  (vitamin  B1)  is  a  water-soluble  vitamin.  Thi-
amine  diphosphate  is  the  active  form  and  serves  as  a
co-factor  to  several  enzymes  involved  primarily  in  car-
bohydrate  catabolism.  Those  enzymes  are  important  in
the  biosynthesis  of  a  number  of  cell  constituents,  includ-
ing  neurotransmitters,  and  for  the  production  of  reducing
equivalents  used  in  oxidant  stress  defenses  and  in  biosyn-
theses  and  for  synthesis  of  pentoses  used  as  nucleic  acid
precursors.The  major  manifestations  of  thiamine  deﬁciency  in
humans  involve  the  cardiovascular  (wet  beriberi)  and  ner-
vous  (dry  beriberi,  neuropathy  and  Wernicke--Korsakoff
syndrome)  systems.7
P
d
a33
WE  is  a  devastating  acute  or  subacute  neurological  disor-
er  and  remains  the  most  important  encephalopathy  due  to
 single  vitamin  deﬁciency.  The  disease  is  rare,  catastrophic
n  onset,  clinically  complex  and  often  delayed  in  diagnosis.
he  reported  prevalence  of  WE  in  autopsy  studies  ranges
rom  0.4%  to  2.8%,  accounting  on  average  for  1.3%  of  all
utopsies,  and  seems  to  be  much  higher  in  alcoholics  than
n  non-alcoholics.8
The  clinical  diagnosis  of  WE  requires  two  of  the  follow-
ng  four  signs:  dietary  deﬁciencies,  eye  signs,  cerebellar
ysfunction,  and  either  altered  mental  state  or  mild  mem-
ry  impairment.8 Whenever  possible,  direct  measurement  of
hiamine  and  its  phosphate  esters  in  human  blood  by  high-
erformance  liquid  chromatography  should  be  performed
efore  thiamine  administration  and  MRI  should  be  used  to
upport  the  diagnosis  of  acute  WE.8
According  to  European  Federation  of  Neurological  Soci-
ties  (EFNS)  guidelines  published  in  2010,  600  cases  of  WE
ere  reported  in  non-alcoholic  patients.  WE  was  typically
ssociated  with  malignant  pathologies,  gastrointestinal  dis-
ases  and  previous  surgeries,  or  resulting  from  vomiting  due
o  hyperemesis  gravidarum.8
There  are  few  reports  in  the  literature  of  patients  with
BD  developing  WE.  Hanh  et  al.  reported  a  case  of  a  female
atient  with  CD  that  was  on  chronic  total  parenteral  nutri-
ion  and  developed  WE  after  a  shortage  of  multivitamin
nfusion  in  the  United  States  and  recovered  after  thiamine
eplacement.9 In  Larnaout  et  al.  report,  a patient  with  CD
ied  due  to  the  lack  of  thiamine  replacement.10 In  another
eport,  a patient  with  CD,  submitted  to  intestinal  resection,
resented  with  neurological  manifestations  and  decreased
hiamine  levels  and  a  signiﬁcant  improvement  after  vitamin
1  infusion  was  observed.11
Similar  to  this  case  study,  Mattioli  et  al.  reported  the
ccurrence  of  WE  in  a  patient  with  complicated  UC  and
otal  parenteral  nutrition,  despite  the  administration  of  the
sually  recommended  doses  of  vitamin  B1.12
Another  unusual  ﬁnding  in  our  patient  was  the  com-
laint  of  dysphagia  and  the  gastric  stasis  that  developed
efore  other  neurologic  ﬁndings  and  recovered  after  thi-
mine  infusion.  Dysphagia  is  an  unusual  ﬁnding  in  WE,
specially  as  presenting  symptom.  Karaiskos13 described
his  same  clinical  presentation  in  an  alcoholic  man  and
ruedsson14 in  a  non-alchoolic  patient.  Gastrointestinal
eriberi  is  referred  in  EFNS  guidelines  as  a  manifestation
f  thiamine  deﬁciency.8
WE  is  potentially  lethal  in  a  short  time  if  not  promptly
ecognized  and  treated.  In  severely  malnourished  patients,
tandard  doses  of  thiamine  in  multivitamin  infusion  may
ot  be  sufﬁcient.  This  diagnosis  should  be  suspected  if
eurologic  symptoms  develop  in  this  context.  We  believe
hat  prophylactic  additional  supplementation  of  thiamine
s  reasonable  in  malnourished  patients  receiving  enteral  or
arenteral  nutrition  in  order  to  avoid  thiamine  deﬁciency
omplications.rotection  of  human  and  animal  subjects.  The  authors
eclare  that  no  experiments  were  performed  on  humans  or
nimals  for  this  investigation.
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